Cancer and Breakthrough Pain

This study, sponsored by Cephalon, Inc., is designed to evaluate the safety and effectiveness of an investigational drug, ACTIQ, for the management of breakthrough pain for patients with cancer. Patients ages 3 through 15 must already be receiving around-the-clock opioid therapy and have at least one episode of breakthrough pain a day. Patients will be hospitalized during this study. When an episode of breakthrough pain occurs, a low dose of ACTIQ is placed in the mouth, between the cheek and gum, and dissolved over 15 minutes. Once the most effective dose of ACTIQ is determined to control the patient's pain, four more breakthrough pain episodes will be treated, three with ACTIQ and one with placebo.

For further information about these clinical trials or information about participation, please contact:

Raymond Tannous, MD, Principal Investigator
raymond-tannous@uiowa.edu
or
Marian Andersen, Data Manager
marian-andersen@uiowa.edu